Cost-utility analysis of prenatal diagnosis of congenital cardiac diseases using deep learning.

Autor: Ginsberg GM; Braun School of Public Health, Hebrew University, Jerusalem, Israel. gmginsberg@gmail.com.; HECON, Health Economics Consultancy, Jerusalem, Israel. gmginsberg@gmail.com., Drukker L; Department of Obstetrics and Gynecology, Rabin-Belinson Medical Center, Petah Tikva, Israel.; School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv-Yafo, Israel., Pollak U; Pediatric Critical Care Sector, Hadassah University Medical Center, Jerusalem, Israel.; Faculty of Medicine, Hebrew University Medical Center, Jerusalem, Israel., Brezis M; Braun School of Public Health, Hebrew University, Jerusalem, Israel.; Center for Quality and Safety, Hadassah University Medical Center, Jerusalem, Israel.
Jazyk: angličtina
Zdroj: Cost effectiveness and resource allocation : C/E [Cost Eff Resour Alloc] 2024 May 22; Vol. 22 (1), pp. 44. Date of Electronic Publication: 2024 May 22.
DOI: 10.1186/s12962-024-00550-3
Abstrakt: Background: Deep learning (DL) is a new technology that can assist prenatal ultrasound (US) in the detection of congenital heart disease (CHD) at the prenatal stage. Hence, an economic-epidemiologic evaluation (aka Cost-Utility Analysis) is required to assist policymakers in deciding whether to adopt the new technology.
Methods: The incremental cost-utility ratios (CUR), of adding DL assisted ultrasound (DL-US) to the current provision of US plus pulse oximetry (POX), was calculated by building a spreadsheet model that integrated demographic, economic epidemiological, health service utilization, screening performance, survival and lifetime quality of life data based on the standard formula: CUR = Increase in Intervention Costs - Decrease in Treatment costs Averted QALY losses of adding DL to US & POX US screening data were based on real-world operational routine reports (as opposed to research studies). The DL screening cost of 145 USD was based on Israeli US costs plus 20.54 USD for reading and recording screens.
Results: The addition of DL assisted US, which is associated with increased sensitivity (95% vs 58.1%), resulted in far fewer undiagnosed infants (16 vs 102 [or 2.9% vs 15.4%] of the 560 and 659 births, respectively). Adoption of DL-US will add 1,204 QALYs. with increased screening costs 22.5 million USD largely offset by decreased treatment costs (20.4 million USD). Therefore, the new DL-US technology is considered "very cost-effective", costing only 1,720 USD per QALY. For most performance combinations (sensitivity > 80%, specificity > 90%), the adoption of DL-US is either cost effective or very cost effective. For specificities greater than 98% (with sensitivities above 94%), DL-US (& POX) is said to "dominate" US (& POX) by providing more QALYs at a lower cost.
Conclusion: Our exploratory CUA calculations indicate the feasibility of DL-US as being at least cost-effective.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje